SCOTT ALAN HACKER
- Type
- Physician · Allopathic & Osteopathic Physicians / Orthopaedic Surgery / Sports Medicine
- Where
- LA MESA, CA
- NPI
- 1750450805
- Received
- $931,437 in 205 records, 2019 to 2025 ($434,027 general, $497,409 research)
- As principal investigator
- $2,560,898 of research payments to others in 221 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 12 | $4,388 |
| 2025 | Research payment | 4 | $10,391 |
| 2024 | General payment | 8 | $513 |
| 2024 | Research payment | 13 | $222,622 |
| 2023 | General payment | 11 | $9,221 |
| 2023 | Research payment | 18 | $264,396 |
| 2022 | General payment | 27 | $31,956 |
| 2021 | General payment | 61 | $124,658 |
| 2020 | General payment | 24 | $137,392 |
| 2019 | General payment | 27 | $125,896 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Heron Therapeutics, Inc. | 72 | $328,713 | 2019–2022 |
| Episurf Medical, Inc. | 25 | $312,416 | 2023–2025 |
| Aesculap Biologics, LLC | 18 | $185,578 | 2019–2023 |
| Anika Therapeutics, Inc. | 11 | $61,233 | 2020–2021 |
| Bioventus LLC | 31 | $37,312 | 2019–2025 |
| Smith+Nephew, Inc. | 4 | $4,005 | 2021–2025 |
| Stryker Corporation | 23 | $1,190 | 2019–2025 |
| Elevate Surgical Co | 2 | $171 | 2024–2025 |
| Zimmer Biomet Holdings, Inc. | 2 | $158 | 2020–2025 |
| ORTHALIGN INC | 1 | $150 | 2023 |
| Cartiheal (2009) LTD. | 1 | $123 | 2023 |
| BIOTISSUE HOLDINGS INC. | 1 | $103 | 2024 |
| Pacira Therapeutics, Inc. | 3 | $54 | 2021 |
| Ethicon US, LLC | 2 | $43 | 2024–2025 |
| SANOFI-AVENTIS U.S. LLC | 2 | $31 | 2019–2023 |
| Merck Sharp & Dohme LLC | 1 | $30 | 2023 |
| DJO, LLC | 1 | $24 | 2019 |
| HERAEUS MEDICAL, LLC. | 1 | $23 | 2022 |
| DePuy Synthes Sales Inc. | 1 | $23 | 2025 |
| MOXIMED, INC | 1 | $18 | 2025 |
| Avanos Medical | 1 | $17 | 2023 |
| PFIZER INC. | 1 | $11 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 35 | $497,409 |
| Consulting Fee | 69 | $408,752 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $17,100 |
| Travel and Lodging | 21 | $4,325 |
| Food and Beverage | 75 | $3,850 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Zimmer Biomet Holdings, Inc. | $128 | Food and Beverage | In-kind items and services | Avenir Device, Hips | 2025 | |
| 2025-10-24 | Stryker Corporation | $56 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2025 | |
| 2025-10-02 | Episurf Medical, Inc. | $4,390 | Research payment | Cash or cash equivalent | Epis Knee Trial | 2025 | |
| 2025-09-02 | MOXIMED, INC | $18 | Food and Beverage | In-kind items and services | MISHA KNEE SYSTEM, SMALL, LEFT Device, ORTHOPEDICS | 2025 | |
| 2025-08-07 | Episurf Medical, Inc. | $2,530 | Research payment | Cash or cash equivalent | Epis Knee Trial | 2025 | |
| 2025-07-31 | Bioventus LLC | $34 | Food and Beverage | In-kind items and services | XCELL Device, DEVICES | 2025 | |
| 2025-06-04 | Elevate Surgical Co | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-22 | Smith+Nephew, Inc. | $55 | Food and Beverage | In-kind items and services | Katalyst Bipolar Radial Head System Device, Extremity, Upper | 2025 | |
| 2025-05-19 | DePuy Synthes Sales Inc. | $23 | Food and Beverage | In-kind items and services | INTRAFIX Device, Sports Surgical | 2025 | |
| 2025-05-02 | Episurf Medical, Inc. | $1,265 | Research payment | Cash or cash equivalent | Epic Knee Trial | 2025 | |
| 2025-04-23 | Stryker Corporation | $23 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2025 | |
| 2025-04-02 | Ethicon US, LLC | $17 | Food and Beverage | In-kind items and services | STRATAFIX Device, Wound Closure | 2025 | |
| 2025-03-06 | Episurf Medical, Inc. | $2,206 | Research payment | Cash or cash equivalent | Epic Knee Trial | 2025 | |
| 2025-02-27 | Smith+Nephew, Inc. | $3,900 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-18 | Stryker Corporation | $71 | Food and Beverage | In-kind items and services | GAMMA Device, TRAUMA & EXTREMETIES | 2025 | |
| 2025-01-15 | Bioventus LLC | $36 | Food and Beverage | In-kind items and services | SUPARTZ FX SODIUM HYALURONATE Device, DEVICES | 2025 | |
| 2024-12-11 | Stryker Corporation | $24 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2024 | |
| 2024-12-09 | Episurf Medical, Inc. | $3,303 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-10-30 | Episurf Medical, Inc. | $3,383 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-10-02 | Episurf Medical, Inc. | $17,330 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-10-02 | Elevate Surgical Co | $147 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-16 | BIOTISSUE HOLDINGS INC. | $103 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-09-10 | Episurf Medical, Inc. | $21,048 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-09-05 | Ethicon US, LLC | $25 | Food and Beverage | In-kind items and services | ETHICON Device, Biosurgical | 2024 | |
| 2024-08-01 | Episurf Medical, Inc. | $11,894 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-07-02 | Episurf Medical, Inc. | $37,034 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-06-13 | Stryker Corporation | $104 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2024 | |
| 2024-06-10 | Episurf Medical, Inc. | $40,895 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-05-02 | Episurf Medical, Inc. | $13,489 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-04-21 | Smith+Nephew, Inc. | $34 | Food and Beverage | In-kind items and services | Panta 2 Device, Extremity, Lower Plates, Screws, and Nails | 2024 | |
| 2024-04-18 | Stryker Corporation | $40 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2024 | |
| 2024-04-03 | Episurf Medical, Inc. | $18,664 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-03-08 | Episurf Medical, Inc. | $4,480 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-02-06 | Stryker Corporation | $32 | Food and Beverage | In-kind items and services | TRIATHLON Device, KNEES | 2024 | |
| 2024-02-01 | Episurf Medical, Inc. | $35,642 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-01-03 | Episurf Medical, Inc. | $8,760 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2024-01-03 | Episurf Medical, Inc. | $6,700 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2024 | |
| 2023-11-08 | Avanos Medical | $17 | Food and Beverage | In-kind items and services | TRIVISC SODIUM HYALURONATE Device, PAIN MANAGEMENT | 2023 | |
| 2023-10-27 | Episurf Medical, Inc. | $2,400 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-10-06 | Episurf Medical, Inc. | $11,089 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-10-05 | Stryker Corporation | $60 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2023 | |
| 2023-10-04 | Aesculap Biologics, LLC | $15,014 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-09-11 | Episurf Medical, Inc. | $1,989 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-08-23 | Aesculap Biologics, LLC | $4,556 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-08-14 | ORTHALIGN INC | $150 | Food and Beverage | Cash or cash equivalent | ORTHALIGN PLUS Device, ORTHOPEDIC SURGERY | 2023 | |
| 2023-08-09 | Aesculap Biologics, LLC | $28,839 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-08-09 | Episurf Medical, Inc. | $18,226 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-08-02 | Stryker Corporation | $23 | Food and Beverage | In-kind items and services | 1688 Device, VISUALIZATION | 2023 | |
| 2023-07-27 | Cartiheal (2009) LTD. | $123 | Food and Beverage | In-kind items and services | Agili-C Device, Sports Med Knee | 2023 | |
| 2023-07-10 | Episurf Medical, Inc. | $13,980 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-07-05 | Aesculap Biologics, LLC | $14,687 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-06-14 | SANOFI-AVENTIS U.S. LLC | $14 | Food and Beverage | In-kind items and services | SYNVISC-ONE Device, Orthopedics/Orthopedic Surgery | 2023 | |
| 2023-06-09 | Episurf Medical, Inc. | $5,293 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-06-06 | Bioventus LLC | $1,600 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-30 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | BRIDION Drug, NEUROSCIENCE | 2023 | |
| 2023-05-24 | Aesculap Biologics, LLC | $11,497 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-05-02 | Episurf Medical, Inc. | $23,076 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-04-26 | Aesculap Biologics, LLC | $29,126 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-03-15 | Episurf Medical, Inc. | $3,350 | Research payment | Cash or cash equivalent | EPIC-Knee Episealer Knee System IDE Clinical Study | 2023 | |
| 2023-03-01 | Aesculap Biologics, LLC | $32,942 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-02-01 | Aesculap Biologics, LLC | $19,001 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-02-01 | Aesculap Biologics, LLC | $21 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-01-06 | Bioventus LLC | $4,800 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-06 | Bioventus LLC | $1,600 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-06 | Bioventus LLC | $800 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-04 | Aesculap Biologics, LLC | $29,305 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2022-10-26 | Bioventus LLC | $1,631 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-09-29 | Bioventus LLC | $700 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-27 | Aesculap Biologics, LLC | $71 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2022 | |
| 2022-08-17 | Bioventus LLC | $700 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-20 | Stryker Corporation | $27 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2022 | |
| 2022-07-07 | Bioventus LLC | $8,225 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $5,425 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $4,987 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $815 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $42 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $38 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $35 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $35 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $30 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-07 | Bioventus LLC | $25 | Food and Beverage | Cash or cash equivalent | 2022 | ||
| 2022-05-15 | Bioventus LLC | $46 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-13 | Bioventus LLC | $99 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-11 | Bioventus LLC | $2,800 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-11 | HERAEUS MEDICAL, LLC. | $23 | Food and Beverage | In-kind items and services | PALACOS Device, BONE CEMENT | 2022 | |
| 2022-05-11 | Aesculap Biologics, LLC | $14 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2022 | |
| 2022-03-23 | Heron Therapeutics, Inc. | $250 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2022 | |
| 2022-02-25 | Aesculap Biologics, LLC | $116 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2022 | |
| 2022-02-17 | Bioventus LLC | $377 | Travel and Lodging | In-kind items and services | Other Device, Not Applicable | 2022 | |
| 2022-02-17 | Bioventus LLC | $79 | Travel and Lodging | In-kind items and services | Other Device, Not Applicable | 2022 | |
| 2022-02-17 | Bioventus LLC | $79 | Travel and Lodging | In-kind items and services | Other Device, Not Applicable | 2022 | |
| 2022-02-16 | Stryker Corporation | $31 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2022 | |
| 2022-02-15 | Heron Therapeutics, Inc. | $5,250 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2022 | |
| 2021-12-21 | Anika Therapeutics, Inc. | $2,225 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-12-10 | Anika Therapeutics, Inc. | $10,385 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-18 | Heron Therapeutics, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-11-18 | Heron Therapeutics, Inc. | $564 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-11-18 | Heron Therapeutics, Inc. | $417 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-11-18 | Heron Therapeutics, Inc. | $122 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-10-14 | Anika Therapeutics, Inc. | $4,950 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-13 | Bioventus LLC | $24 | Food and Beverage | In-kind items and services | GELSYN-3 Device, Not Applicable | 2021 | |
| 2021-10-12 | Bioventus LLC | $700 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-08 | Anika Therapeutics, Inc. | $709 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-10-05 | Stryker Corporation | $34 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-09-30 | Heron Therapeutics, Inc. | $2,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-30 | Heron Therapeutics, Inc. | $313 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-30 | Heron Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-30 | Heron Therapeutics, Inc. | $67 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $540 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $182 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $131 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $27 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $5 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-29 | Heron Therapeutics, Inc. | $2 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-09-15 | Pacira Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Zilretta Drug, Musculoskeletal | 2021 | |
| 2021-09-03 | Stryker Corporation | $52 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-08-31 | Stryker Corporation | $46 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-08-23 | Aesculap Biologics, LLC | $105 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2021 | |
| 2021-08-16 | Bioventus LLC | $1,400 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-07-13 | Stryker Corporation | $46 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-07-01 | Heron Therapeutics, Inc. | $9,625 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-30 | Stryker Corporation | $65 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-06-28 | Pacira Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Zilretta Drug, Musculoskeletal | 2021 | |
| 2021-06-23 | Heron Therapeutics, Inc. | $8,125 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-23 | Heron Therapeutics, Inc. | $282 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-23 | Heron Therapeutics, Inc. | $144 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-23 | Heron Therapeutics, Inc. | $139 | Travel and Lodging | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-15 | Heron Therapeutics, Inc. | $1,425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-10 | Anika Therapeutics, Inc. | $709 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-01 | Heron Therapeutics, Inc. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-06-01 | Heron Therapeutics, Inc. | $30 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-05-30 | Heron Therapeutics, Inc. | $33 | Food and Beverage | In-kind items and services | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-05-27 | Heron Therapeutics, Inc. | $250 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-05-26 | Heron Therapeutics, Inc. | $19,500 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-05-26 | Heron Therapeutics, Inc. | $1,000 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-05-25 | Heron Therapeutics, Inc. | $6,750 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-05-20 | Aesculap Biologics, LLC | $117 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2021 | |
| 2021-04-28 | Bioventus LLC | $23 | Food and Beverage | In-kind items and services | Durolane Device, Orthopedics/Orthopedic Surgery | 2021 | |
| 2021-04-22 | Heron Therapeutics, Inc. | $3,625 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-04-20 | Stryker Corporation | $50 | Food and Beverage | In-kind items and services | MAKO Device, KNEES, HIPS | 2021 | |
| 2021-04-15 | Anika Therapeutics, Inc. | $1,447 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-03-26 | Heron Therapeutics, Inc. | $3,125 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-03-19 | Stryker Corporation | $40 | Food and Beverage | In-kind items and services | RESTORATION Device, HIPS | 2021 | |
| 2021-03-17 | Smith+Nephew, Inc. | $16 | Food and Beverage | In-kind items and services | EVOS Device, Trauma Plates, Screws, and Nails | 2021 | |
| 2021-03-09 | Stryker Corporation | $7 | Food and Beverage | In-kind items and services | TRITANIUM Device, HIPS | 2021 | |
| 2021-02-09 | Pacira Therapeutics, Inc. | $17 | Food and Beverage | In-kind items and services | Zilretta Drug, Musculoskeletal | 2021 | |
| 2021-02-03 | Anika Therapeutics, Inc. | $16,558 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-01-21 | Heron Therapeutics, Inc. | $2,125 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-01-07 | Heron Therapeutics, Inc. | $8,000 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2021-01-07 | Heron Therapeutics, Inc. | $2,375 | Consulting Fee | Cash or cash equivalent | Zynrelef Drug, Postoperative Pain | 2021 | |
| 2020-12-04 | Anika Therapeutics, Inc. | $1,269 | Consulting Fee | Cash or cash equivalent | Hyalofast Device, Musculoskeletal | 2020 | |
| 2020-11-24 | Heron Therapeutics, Inc. | $2,250 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-11-05 | Anika Therapeutics, Inc. | $2,345 | Consulting Fee | Cash or cash equivalent | Hyalofast Device, Musculoskeletal | 2020 | |
| 2020-10-23 | Heron Therapeutics, Inc. | $3,875 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-10-15 | Stryker Corporation | $17 | Food and Beverage | Cash or cash equivalent | TRIATHLON Device, KNEES | 2020 | |
| 2020-10-05 | Heron Therapeutics, Inc. | $2,625 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-10-02 | Anika Therapeutics, Inc. | $14,336 | Consulting Fee | Cash or cash equivalent | Hyalofast Device, Musculoskeletal | 2020 | |
| 2020-10-02 | Heron Therapeutics, Inc. | $250 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-09-21 | Heron Therapeutics, Inc. | $17,375 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-09-21 | Heron Therapeutics, Inc. | $2,250 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-08-03 | Heron Therapeutics, Inc. | $4,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-08-03 | Heron Therapeutics, Inc. | $1,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-06-29 | Heron Therapeutics, Inc. | $19,875 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-06-29 | Heron Therapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-04-28 | Heron Therapeutics, Inc. | $23,325 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-04-13 | Heron Therapeutics, Inc. | $500 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-03-11 | Stryker Corporation | $61 | Food and Beverage | Cash or cash equivalent | MAKO Device, KNEES, HIPS | 2020 | |
| 2020-03-11 | Zimmer Biomet Holdings, Inc. | $29 | Food and Beverage | In-kind items and services | EBI Bone Healing System Device, Bone Healing | 2020 | |
| 2020-03-05 | Heron Therapeutics, Inc. | $22,975 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-03-05 | Heron Therapeutics, Inc. | $4,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-03-05 | Heron Therapeutics, Inc. | $3,250 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-03-01 | Heron Therapeutics, Inc. | $3,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2020 | |
| 2020-02-26 | Anika Therapeutics, Inc. | $6,300 | Consulting Fee | Cash or cash equivalent | Hyalofast Device, Musculoskeletal | 2020 | |
| 2020-02-04 | Bioventus LLC | $107 | Food and Beverage | In-kind items and services | 2020 | ||
| 2019-12-13 | Heron Therapeutics, Inc. | $4,250 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-11-21 | Heron Therapeutics, Inc. | $3,750 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-11-15 | Heron Therapeutics, Inc. | $5,000 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-10-30 | SANOFI-AVENTIS U.S. LLC | $16 | Food and Beverage | In-kind items and services | SYNVISC-ONE Device, OSTEOARTHRITIS | 2019 | |
| 2019-10-10 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2019 | |
| 2019-09-28 | Heron Therapeutics, Inc. | $42 | Food and Beverage | In-kind items and services | HTX-011 Drug | 2019 | |
| 2019-09-28 | Heron Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | HTX-011 Drug | 2019 | |
| 2019-09-28 | Heron Therapeutics, Inc. | $7 | Food and Beverage | In-kind items and services | HTX-011 Drug | 2019 | |
| 2019-09-25 | Heron Therapeutics, Inc. | $10,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-09-16 | Heron Therapeutics, Inc. | $17,500 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-09-13 | Heron Therapeutics, Inc. | $1,000 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-09-13 | Heron Therapeutics, Inc. | $750 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-09-04 | DJO, LLC | $24 | Food and Beverage | In-kind items and services | CMF OL1000 Device, Osteogenesis Stimulators | 2019 | |
| 2019-08-14 | Heron Therapeutics, Inc. | $6,625 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-07-24 | Heron Therapeutics, Inc. | $5,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-07-19 | Aesculap Biologics, LLC | $12 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2019 | |
| 2019-07-18 | Aesculap Biologics, LLC | $133 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2019 | |
| 2019-06-10 | Heron Therapeutics, Inc. | $4,125 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-05-17 | Heron Therapeutics, Inc. | $21,625 | Consulting Fee | Cash or cash equivalent | HTX-011 Drug | 2019 | |
| 2019-05-09 | Stryker Corporation | $119 | Food and Beverage | Cash or cash equivalent | TRIATHLON Device, KNEES | 2019 | |
| 2019-05-08 | Bioventus LLC | $14 | Food and Beverage | In-kind items and services | Supartz Device, Not Applicable | 2019 | |
| 2019-04-25 | Aesculap Biologics, LLC | $14 | Food and Beverage | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | 2019 |
The latest 200 records of 205.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-05 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $10,000 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for | 2025 |
| 2025-10-06 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $32,650 | TTAX03-CR005 | 2025 |
| 2025-09-23 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $596 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for | 2025 |
| 2025-08-26 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $3,466 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for | 2025 |
| 2025-05-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $16,719 | TTAX03-CR005 | 2025 |
| 2025-04-08 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,140 | TTAX03-CR005 | 2025 |
| 2025-03-05 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,800 | TTAX03-CR005 | 2025 |
| 2025-03-05 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $6,000 | TTAX03-CR005 | 2025 |
| 2025-03-05 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $11,400 | TTAX03-CR005 | 2025 |
| 2025-03-05 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $15,600 | TTAX03-CR005 | 2025 |
| 2025-03-05 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $17,849 | TTAX03-CR005 | 2025 |
| 2025-03-04 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $4,300 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for | 2025 |
| 2025-02-18 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $8,125 | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety | 2025 |
| 2025-02-10 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $5,656 | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety | 2025 |
| 2025-01-30 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $7,062 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2025 |
| 2025-01-28 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $35,315 | A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety | 2025 |
| 2025-01-22 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $334 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $16 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2025 |
| 2024-12-16 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $5,840 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2024 |
| 2024-11-15 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $3,640 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2024 |
| 2024-11-05 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $2,713 | TTAX03-CR005 | 2024 |
| 2024-10-07 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $1,105 | TTAX03-CR005 | 2024 |
| 2024-10-01 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $16,000 | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety | 2024 |
| 2024-09-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $6,600 | TTAX03-CR005 | 2024 |
| 2024-09-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $9,687 | TTAX03-CR005 | 2024 |
| 2024-08-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $6,600 | TTAX03-CR005 | 2024 |
| 2024-08-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $9,419 | TTAX03-CR005 | 2024 |
| 2024-08-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $1,200 | TTAX03-CR005 | 2024 |
| 2024-08-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $28,800 | TTAX03-CR005 | 2024 |
| 2024-07-17 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $8,857 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-07-10 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $8,368 | TTAX03-CR005 | 2024 |
| 2024-07-09 | Anika Therapeutics, Inc. | HORIZON CLINICAL RESEARCH | $6,205 | A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority | 2024 |
| 2024-06-20 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $12,428 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-06-13 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $24,380 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2024 |
| 2024-06-11 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $3,679 | TTAX03-CR005 | 2024 |
| 2024-06-11 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $6,000 | TTAX03-CR005 | 2024 |
| 2024-05-31 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $910 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2024 |
| 2024-05-22 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $9,644 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-05-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $8,741 | TTAX03-CR005 | 2024 |
| 2024-04-17 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $5,505 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-04-10 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $18,284 | TTAX03-CR005 | 2024 |
| 2024-04-08 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $365 | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety | 2024 |
| 2024-03-15 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $5,275 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,800 | TTAX03-CR005 | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,800 | TTAX03-CR005 | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $9,000 | TTAX03-CR005 | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $31,387 | TTAX03-CR005 | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,800 | TTAX03-CR005 | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,800 | TTAX03-CR005 | 2024 |
| 2024-03-12 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $4,800 | TTAX03-CR005 | 2024 |
| 2024-03-04 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $100 | A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety | 2024 |
| 2024-02-21 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $10,129 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-02-12 | Anika Therapeutics, Inc. | HORIZON CLINICAL RESEARCH | $2,298 | A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority | 2024 |
| 2024-02-09 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $34,986 | TTAX03-CR005 | 2024 |
| 2024-02-02 | Smith+Nephew, Inc. | HORIZON CLINICAL RESEARCH | $1,690 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2024 |
| 2024-01-31 | Aesculap Biologics, LLC | HORIZON CLINICAL RESEARCH INC | $10,161 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2024 |
| 2024-01-15 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $104,605 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2024 |
| 2024-01-10 | BIOTISSUE HOLDINGS INC. | HORIZON CLINICAL RESEARCH | $32,566 | TTAX03-CR005 | 2024 |
| 2024-01-03 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $26,395 | A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety | 2024 |
| 2023-11-09 | Anika Therapeutics, Inc. | HORIZON CLINICAL RESEARCH | $1,800 | A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority | 2023 |
| 2023-10-25 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $1,000 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE | 2023 |
| 2023-10-23 | Cartiheal (2009) LTD. | HORIZON CLINICAL RESEARCH | $910 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2023 |
| 2023-10-16 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $7,500 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2023 |
| 2023-10-12 | Anika Therapeutics, Inc. | HORIZON CLINICAL RESEARCH | $921 | A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority | 2023 |
| 2023-09-25 | Cartiheal (2009) LTD. | HORIZON CLINICAL RESEARCH | $1,820 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2023 |
| 2023-09-20 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $1,500 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2023 |
| 2023-09-13 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $500 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2023 |
| 2023-08-03 | Cartiheal (2009) LTD. | HORIZON CLINICAL RESEARCH | $910 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2023 |
| 2023-08-03 | Cartiheal (2009) LTD. | HORIZON CLINICAL RESEARCH | $1,820 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2023 |
| 2023-07-14 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $763 | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficac | 2023 |
| 2023-06-07 | Cartiheal (2009) LTD. | HORIZON CLINICAL RESEARCH | $1,820 | A Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t | 2023 |
| 2023-04-03 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $38,591 | A randomized placebo controlled patient and investigator blinded Proof of Concept study investigating the safety tolerab | 2023 |
| 2023-03-22 | Aesculap Biologics, LLC | SAN DIEGO STATE UNIVERSITY | $4,725 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-03-15 | Novartis Pharmaceuticals Corporation | SCOTT A HACKER MD MEDICAL CORPORATI HORIZON CLINICAL RESEARCH | $78,947 | A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety | 2023 |
| 2023-02-22 | Aesculap Biologics, LLC | SAN DIEGO STATE UNIVERSITY | $1,574 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2023 |
| 2023-02-17 | Anika Therapeutics, Inc. | HORIZON CLINICAL RESEARCH | $2,898 | A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority | 2023 |
| 2023-01-25 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $1,300 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2023 |
| 2023-01-24 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $281,481 | A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety | 2023 |
| 2022-11-16 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $6,000 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE | 2022 |
| 2022-11-09 | Aesculap Biologics, LLC | SCOTT HACKER MD MEDICAL CORP | $11,609 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-11-03 | Bioventus LLC | HORIZON CLINICAL RESEARCH | $4,930 | Agili-C Post Approval | 2022 |
| 2022-10-26 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $3,200 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF EN3835 FOR THE TREATMENT OF ADHESIVE | 2022 |
| 2022-10-19 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $14,400 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2022 |
| 2022-10-19 | Aesculap Biologics, LLC | SCOTT HACKER MD MEDICAL CORP | $31,366 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-10-05 | Aesculap Biologics, LLC | SCOTT HACKER MD MEDICAL CORP | $33,158 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-09-30 | Bioventus LLC | HORIZON CLINICAL RESEARCH | $910 | Agili-C Post Approval | 2022 |
| 2022-09-22 | Anika Therapeutics, Inc. | HORIZON CLINICAL RESEARCH | $500 | A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority | 2022 |
| 2022-08-24 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $3,550 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2022 |
| 2022-08-17 | Bioventus LLC | HORIZON CLINICAL RESEARCH | $375 | Agili-C Post Approval | 2022 |
| 2022-08-03 | Aesculap Biologics, LLC | SCOTT HACKER MD MEDICAL CORP | $38,056 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-07-12 | Aesculap Biologics, LLC | Western Institutional Review Board | $1,760 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-07-12 | Aesculap Biologics, LLC | Western Institutional Review Board | $560 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-07-12 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $5,050 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2022 |
| 2022-07-07 | Bioventus LLC | HORIZON CLINICAL RESEARCH | $5,330 | Agili-C Post Approval | 2022 |
| 2022-06-29 | Aesculap Biologics, LLC | SCOTT HACKER MD MEDICAL CORP | $18,999 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-06-28 | Novartis Pharmaceuticals Corporation | HORIZON CLINICAL RESEARCH | $2,387 | A RANDOMIZED, FOUR-ARM, PLACEBO-CONTROLLED, PARTICIPANT, INVESTIGATOR AND SPONSOR-BLINDED STUDY INVESTIGATING THE SAFETY | 2022 |
| 2022-06-22 | Aesculap Biologics, LLC | SAN DIEGO STATE UNIVERSITY | $6,300 | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE (N3D) | 2022 |
| 2022-06-16 | Bioventus LLC | HORIZON CLINICAL RESEARCH | $910 | Agili-C Post Approval | 2022 |
| 2022-06-15 | Aesculap Biologics, LLC | Western Institutional Review Board | $1,315 | SAFETY AND EFFICACY OF NOVOCART 3D IN THE TREATMENT OF ARTICULAR CARTILAGE DEFECTS FOLLOWING FAILURE ON MICROFRACTURE | 2022 |
| 2022-06-14 | Endo Pharmaceuticals Inc. | HORIZON CLINICAL RESEARCH | $3,550 | Observational, Investigator blinded, Long-Term Post-injection Study to Evaluate the Safety and Durability (Efficacy) of | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In La Mesa, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) La Mesa, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 60,797 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 61,121 | 3,298,634 | 39,538,223 |
| Median age B01002 | 37.4 | 37.3 | 37.9 |
| Under 18 B01001 | 21.7% | 20.9% | 22.0% |
| 65 and over B01001 | 15.5% | 15.4% | 15.7% |
| Households B11001 | 25,038 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 13.1% | 22.8% | 27.0% |
| Median household income B19013 | $95,028 | $106,268 | $99,122 |
| Median family income B19113 | $117,152 | $122,377 | $113,346 |
| Per capita income B19301 | $49,543 | $51,976 | $49,513 |
| Poverty rate B17001 | 11.5% | 10.3% | 12.0% |
| Unemployment rate B23025 | 6.2% | 6.1% | 6.6% |
| Civilian labor force B23025 | 32,408 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 23.8 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 40.6% | 43.2% | 37.1% |
| Housing units B25001 | 26,212 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 47.7% | 54.6% | 55.9% |
| Renters B25003 | 52.3% | 45.4% | 44.1% |
| Median home value B25077 | $812,000 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,049 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 50.8% | 42.4% | 33.8% |
| Black B03002 | 7.7% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 27.9% | 34.6% | 40.2% |
| Asian B03002 | 5.9% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in La Mesa, CA.
Comments